SEARCH ARTICLES  

Intermittent androgen deprivation (IAD) for advance prostate cancer. Why not the standard of therapy?
Dominique Prapotnich, Rafael Sanchez-Salas, Xavier Cathelineau, Oleksandr Stakhovskyi, José EA Rocha Jr and Guy Vallancien.

JOURNAL
Tomo 62. Número 09 - Noviembre 2009

REFERENCE
Arch. Esp. Urol. 2009; 62 (9): 689-694

KEYWORDS
Intermittent hormone treatment. Prostate cancer. Androgen blockade. Castration. Androgen antagonists.

OBJECTIVES
To review the literature and present a contemporary image of androgen deprivation for prostate cancer.

METHODS
We conducted a PubMed search on intermittent androgen deprivation. Articles obtained on intermittent androgen deprivation (IAD) and the experiences at Institut Montsouris were used for the review.

RESULTS
IAD is an approach to hormonal deprivation that holds effective cancer control while preventing the morbidity associated with continuous androgen blockade. IAD nuances have been assessed by urological community teams in order to verify its possible potential benefits. Evidence based approach supports the idea of IAD as a standard of therapy for advanced prostate cancer requiring hormone deprivation. Variation among medical teams’ criteria for the treatment and surveillance await standardization.

CONCLUSIONS
Reassessing the gold standard of hormonal blockade in advanced prostate cancer is mandatory. The undeniable evolution of IAD needs to be embraced by the urological community.




Go back | View article